Delineating the intra-patient heterogeneity of molecular alterations in treatment-naive colorectal cancer with peritoneal carcinomatosis.

ABSTRACT: In a non-negligible number of patients with metastatic colorectal cancer (mCRC), the peritoneum is the predominant site of dissemination. Cure can be achieved by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), but this procedure is associated with long-term morbidity and high relapse rates. Thus, there is a pressing need for improved therapeutic strategies and complementary biomarkers. The present study explored the molecular heterogeneity in mCRC with peritoneal carcinomatosis (PC), and the potential clinical implications thereof. Multi-region immunohistochemical profiling and deep targeted DNA-sequencing was performed on chemotherapy-naïve tumours from seven patients with synchronous colorectal PC who underwent CRS and HIPEC. In total, 88 samples (5-19

SUBMITTER: Siesing C 

PROVIDER: S-EPMC9249627 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature